SG10201800982QA - Humanized or chimeric cd3 antibodies - Google Patents

Humanized or chimeric cd3 antibodies

Info

Publication number
SG10201800982QA
SG10201800982QA SG10201800982QA SG10201800982QA SG10201800982QA SG 10201800982Q A SG10201800982Q A SG 10201800982QA SG 10201800982Q A SG10201800982Q A SG 10201800982QA SG 10201800982Q A SG10201800982Q A SG 10201800982QA SG 10201800982Q A SG10201800982Q A SG 10201800982QA
Authority
SG
Singapore
Prior art keywords
humanized
chimeric
antibodies
Prior art date
Application number
SG10201800982QA
Inventor
Den Brink Edward Van
Joost J Neijssen
Aran Frank Labrijn
Joyce Meesters
Janine Schuurman
Paul Parren
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/064330 external-priority patent/WO2014006217A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of SG10201800982QA publication Critical patent/SG10201800982QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10201800982QA 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies SG10201800982QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2013/064330 WO2014006217A1 (en) 2012-07-06 2013-07-05 Dimeric protein with triple mutations
PCT/EP2014/050340 WO2014108483A1 (en) 2013-01-10 2014-01-09 Inert format
DKPA201400009 2014-01-09

Publications (1)

Publication Number Publication Date
SG10201800982QA true SG10201800982QA (en) 2018-03-28

Family

ID=52143134

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201510739TA SG11201510739TA (en) 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies
SG10201800982QA SG10201800982QA (en) 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201510739TA SG11201510739TA (en) 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies

Country Status (32)

Country Link
US (5) US10465006B2 (en)
EP (5) EP3016681B1 (en)
JP (7) JP6546162B2 (en)
KR (4) KR102363220B1 (en)
CN (5) CN113248615B (en)
AU (4) AU2014286116A1 (en)
BR (1) BR122023002590B1 (en)
CA (1) CA2915575A1 (en)
CY (1) CY1122840T1 (en)
DK (2) DK3016681T5 (en)
EA (1) EA201690167A1 (en)
ES (3) ES2776706T3 (en)
FI (2) FI4249515T3 (en)
FR (1) FR25C1054I1 (en)
HR (2) HRP20200382T1 (en)
HU (3) HUE048722T2 (en)
IL (4) IL311371B2 (en)
LT (3) LT3016681T (en)
ME (1) ME03675B (en)
MX (2) MX373245B (en)
NL (1) NL301352I2 (en)
NO (1) NO2025057I1 (en)
NZ (1) NZ715896A (en)
PL (2) PL3016681T3 (en)
PT (2) PT3016681T (en)
RS (2) RS60131B1 (en)
SG (2) SG11201510739TA (en)
SI (2) SI3016681T1 (en)
SM (2) SMT202000287T1 (en)
UA (1) UA119646C2 (en)
WO (2) WO2015001085A1 (en)
ZA (1) ZA201800385B (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3434767T (en) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
CN104736174B (en) 2012-07-06 2019-06-14 根马布私人有限公司 Dimeric protein with triple mutation
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibody containing chimeric constant region
ME03675B (en) 2013-07-05 2020-10-20 Genmab As HUMANIZED OR CHIMERAL ANTI-CD3 ANTIBODIES
CN105722859B (en) 2013-07-25 2021-05-07 西托姆克斯治疗公司 Multispecific antibodies, multispecific activatable antibodies, and methods of use thereof
TWI701042B (en) * 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
AU2015244814B2 (en) * 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MX2016014434A (en) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function.
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
KR102614189B1 (en) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Methods for tumor treatment using cd3xcd20 bispecific antibody
PT3221356T (en) 2014-11-20 2020-10-29 Hoffmann La Roche T cell activating bispecific antigen binding molecules agiant folr1 and cd3
DK3221357T3 (en) 2014-11-20 2020-08-10 Hoffmann La Roche Common light chains and methods of use
US10544220B2 (en) 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
TWI703159B (en) * 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma-specific therapeutic antibodies and their uses
IL256562B2 (en) 2015-07-15 2024-07-01 Genmab As Humanized or chimeric cd3 antibodies
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
WO2017086419A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Method for enhancing humoral immune response
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
CN105296421B (en) * 2015-11-24 2019-01-29 高岱清 The T cell and preparation method of a kind of activation of bispecific antibody and application
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CN116769054A (en) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 Bispecific signaling agents and uses thereof
JP7015244B2 (en) * 2016-03-22 2022-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Protease-activated T cell bispecific molecule
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
WO2018220099A1 (en) 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
RU2769282C2 (en) 2016-06-20 2022-03-30 Кимаб Лимитед Anti-pd-l1 and il-2 cytokines
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN110573172A (en) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 Targeted engineered interferon and uses thereof
DK3592769T3 (en) 2017-03-09 2024-08-12 Genmab As ANTIBODIES AGAINST PD-L1
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN118894936A (en) * 2017-05-08 2024-11-05 阿迪马布有限责任公司 Anti-CD3 binding domains and antibodies comprising the same and methods of producing and using the same
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
AR112257A1 (en) 2017-06-21 2019-10-09 Gilead Sciences Inc MULTI-SPECIFIC ANTIBODIES TARGETING HIV-1 GP120 AND HUMAN CD3, COMPOSITIONS THAT UNDERSTAND THEM, NUCLEIC ACID, RELATED VECTOR AND HOST CELL, METHOD TO PRODUCE THEM, METHOD TO DETECT THEM, METHOD OF DETECTING ANPOSITION OF KEYS1 AND EXPEDITED CD3 CELLS TO GP120 AND METHOD TO PRODUCE THEM
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
WO2019034580A1 (en) 2017-08-14 2019-02-21 Morphosys Ag Humanized antibodies for cd3
US20190100587A1 (en) * 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR101973060B1 (en) * 2017-10-20 2019-04-26 주식회사 녹십자 Antibody against cd3 and pharmaceutical composition for treating cancer comprising the same
CN107860925B (en) * 2017-11-03 2019-07-12 合肥瀚科迈博生物技术有限公司 For detecting the ELISA detection kit of HuA21 antibody in serum
CN109971725B (en) * 2017-12-28 2024-02-02 上海细胞治疗研究院 Antibody-modified chimeric antigen receptor-modified T cells and uses thereof
JP7337079B2 (en) * 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド Mutant CD3 binding domains and their use in combination therapy for the treatment of disease
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
CN120399075A (en) * 2018-03-14 2025-08-01 诺维莫尼公司 Anti-CD3ε antibodies and their use methods
KR102602329B1 (en) * 2018-05-23 2023-11-16 화이자 인코포레이티드 Antibodies specific for CD3 and their uses
CA3101271A1 (en) * 2018-05-24 2019-11-28 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
JP7611820B2 (en) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド DLL3 single domain antibodies and therapeutic compositions thereof
CN120623346A (en) 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 PD-1 single domain antibody and therapeutic composition thereof
JP2022504802A (en) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド 5T4 single domain antibody and therapeutic composition thereof
CN113166261A (en) 2018-10-11 2021-07-23 印希比股份有限公司 B7H3 single domain antibodies and therapeutic compositions thereof
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020052692A2 (en) * 2018-12-04 2020-03-19 Novartis Ag Binding molecules against cd3 and uses thereof
JP7489407B2 (en) 2019-05-21 2024-05-23 ノバルティス アーゲー CD19 binding molecules and uses thereof
WO2021048423A1 (en) 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
TWI841790B (en) * 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 Antibodies targeting CD3, bispecific antibodies and their uses
CN115666704B (en) 2019-12-13 2025-09-26 比特比德科有限责任公司 Ingestible device for delivering therapeutic agents to the gastrointestinal tract
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
WO2021141996A1 (en) * 2020-01-06 2021-07-15 Cytomx Therapeutics, Inc. Single- and multi-chain polypeptides that bind specifically to cd3 epsilon
JP7789002B2 (en) 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド CD28 single domain antibodies and multivalent and multispecific constructs thereof
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
MX2022009936A (en) 2020-03-18 2022-09-12 Genmab As ANTIBODIES THAT BIND TO THE V-SET DOMAIN CONTAINING THE T CELL ACTIVATION INHIBITOR 1 (B7H4).
CN113563473A (en) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 Tetravalent bispecific antibody, preparation method and application thereof
MX2022013797A (en) 2020-05-08 2022-11-30 Genmab As Bispecific antibodies against cd3 and cd20.
CN116249714A (en) 2020-05-27 2023-06-09 詹森生物科技公司 Proteins comprising CD3 antigen-binding domains and uses thereof
JP7518286B2 (en) 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Multispecific antigen-binding molecules targeting HIV and methods of use
IL300835A (en) 2020-09-02 2023-04-01 Genmab As Antibody therapy
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
KR20230066040A (en) 2020-09-10 2023-05-12 젠맵 에이/에스 Bispecific antibodies to CD3 and CD20 to treat chronic lymphocytic leukemia
CN116782933A (en) 2020-09-10 2023-09-19 健玛保 Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
EP4210745A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CA3190376A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
CA3189883A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
JP2023547329A (en) 2020-10-02 2023-11-10 ジェンマブ エー／エス Antibodies capable of binding to ROR2 and bispecific antibodies that bind to ROR2 and CD3
KR102671734B1 (en) * 2021-04-13 2024-06-04 건국대학교 글로컬산학협력단 NOVEL CANINE CD3ε SPECIFIC ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
TW202244059A (en) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
WO2022234146A1 (en) 2021-05-07 2022-11-10 Genmab A/S PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
CN115558023A (en) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 anti-CD 3 antibodies and uses thereof
EP4413039A1 (en) 2021-10-08 2024-08-14 Genmab A/S Antibodies binding to cd30 and cd3
CN118647402A (en) 2022-01-28 2024-09-13 健玛保 Bispecific antibodies targeting CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
MX2024008833A (en) 2022-01-28 2024-07-25 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma.
MX2024011468A (en) 2022-03-23 2024-09-25 Hoffmann La Roche Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy.
US20250304689A1 (en) 2022-04-13 2025-10-02 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
EP4523697A4 (en) * 2022-05-09 2026-01-07 Hangzhou Viromab Biotech Co Ltd THERAPEUTIC WITH MULTISPECIFIC ANTIBODIES AND USE OF THEM IN TUMOR THERAPY
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
EP4612179A1 (en) 2022-11-02 2025-09-10 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
AR132290A1 (en) 2023-04-05 2025-06-11 Genmab As PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODIES THAT BIND TO CD30 AND CD3
CN121311504A (en) 2023-04-13 2026-01-09 金麦安博股份有限公司 Treatment of lymphoma with bispecific antibodies targeting CD3 and CD20
EP4695308A1 (en) * 2023-09-14 2026-02-18 Invitrogen BioServices India Private Limited Engineered antibodies and uses thereof
EP4590715A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
EP4590714A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025116732A1 (en) * 2023-12-01 2025-06-05 Rijksuniversiteit Groningen Methods and kits for detecting proliferating cells
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (en) 1995-11-03 1997-06-26 김광호 Precharge Circuit of Semiconductor Memory Device
ATE299938T1 (en) 1997-05-02 2005-08-15 Genentech Inc A METHOD FOR PRODUCING MULTI-SPECIFIC ANTIBODIES THAT POSSESS HETEROMULTIMER AND COMMON COMPONENTS
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE10043437A1 (en) 2000-09-04 2002-03-28 Horst Lindhofer Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
DK2314629T4 (en) 2002-07-18 2023-02-06 Merus Nv RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
BRPI0315295C1 (en) * 2002-10-17 2021-05-25 Genmab As isolated human monoclonal antibody, prokaryotic host cell, pharmaceutical composition, bispecific molecule, uses of an antibody, in vitro methods of detecting the presence of cd20 antigen or a cell expressing cd20 in a sample, kit, and expression vector
PT1737891E (en) 2004-04-13 2013-04-16 Hoffmann La Roche Anti-p-selectin antibodies
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
AU2006210724A1 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
JP5142707B2 (en) 2005-02-08 2013-02-13 一般財団法人化学及血清療法研究所 Methods for improving antibodies
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (en) 2006-03-24 2013-01-24 Merck Patent Gmbh Engineered heterodimeric protein domains
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
RS53008B2 (en) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Cross-species-specific cd3-epsilon binding domain
MX2009010611A (en) * 2007-04-03 2010-03-26 Micromet Ag Cross-species-specific bispecific binders.
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
JP6157046B2 (en) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド Method for generating antibody Fc heterodimer molecules using electrostatic steering effect
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
DE102008039957A1 (en) 2008-08-27 2010-03-04 Continental Automotive Gmbh Method for determining an accident severity criterion by means of an acceleration signal and a structure-borne sound signal
JP5397668B2 (en) 2008-09-02 2014-01-22 ソニー株式会社 Storage element and storage device
FR2935974B1 (en) 2008-09-15 2010-10-08 Centre Nat Rech Scient DERIVATIVES OF METALLOPORPHYRINS, NANOPARTICLES COMPRISING THE SAME
EP2352765B1 (en) * 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
JP2012505654A (en) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド Methods for humanizing and affinity maturating antibodies
DK2786762T3 (en) 2008-12-19 2019-05-06 Macrogenics Inc COVALENT DIABODIES AND APPLICATIONS THEREOF
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US8786135B2 (en) 2010-03-25 2014-07-22 Mitsubishi Electric Research Laboratories, Inc. Wireless energy transfer with anisotropic metamaterials
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
TWI653333B (en) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 Cross-species specific PSMAxCD3 bispecific single chain antibody
HRP20241208T1 (en) 2010-04-20 2024-11-22 Genmab A/S HETERODIMER PROTEINS CONTAINING FC FRAGMENT OF ANTIBODIES AND PROCEDURES FOR THEIR PRODUCTION
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
TW201208703A (en) * 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
CN103068847B (en) 2010-08-24 2019-05-07 罗切格利卡特公司 Activatable Bispecific Antibodies
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibodies comprising disulfide-stabilized Fv fragments
ES2758994T3 (en) 2010-11-05 2020-05-07 Zymeworks Inc Stable heterodimeric antibody design with mutations in the Fc domain
PT3434767T (en) * 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
EP2678358B1 (en) * 2011-02-23 2015-07-22 F.Hoffmann-La Roche Ag Antibodies against human il33r and uses thereof
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
KR102060389B1 (en) 2011-05-21 2019-12-31 마크로제닉스, 인크. Cd3-binding molecules capable of binding to human and non-human cd3
CN102250246A (en) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 Bispecific antibody to VEGF/PDGFR beta and application thereof
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
DK2807188T3 (en) * 2012-01-27 2019-10-07 Prothena Biosciences Ltd HUMANIZED ANTIBODIES RECOGNIZING ALPHA SYNUCLEIN
CN104736174B (en) 2012-07-06 2019-06-14 根马布私人有限公司 Dimeric protein with triple mutation
ME03675B (en) 2013-07-05 2020-10-20 Genmab As HUMANIZED OR CHIMERAL ANTI-CD3 ANTIBODIES
WO2015006749A2 (en) * 2013-07-12 2015-01-15 Zymeworks Inc. Bispecific cd3 and cd19 antigen binding contructs
IL263466B2 (en) * 2013-12-17 2023-10-01 Genentech Inc Anti-cd3 antibodies and methods of use
US10544220B2 (en) * 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
IL256562B2 (en) 2015-07-15 2024-07-01 Genmab As Humanized or chimeric cd3 antibodies
CH713600A2 (en) 2017-03-21 2018-09-28 Digi Sens Ag Apparatus and method for measuring a load.
WO2019034580A1 (en) * 2017-08-14 2019-02-21 Morphosys Ag Humanized antibodies for cd3
CA3189883A1 (en) * 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
CN116782933A (en) * 2020-09-10 2023-09-19 健玛保 Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
KR20230066040A (en) * 2020-09-10 2023-05-12 젠맵 에이/에스 Bispecific antibodies to CD3 and CD20 to treat chronic lymphocytic leukemia
US20240034812A1 (en) * 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma

Also Published As

Publication number Publication date
EP3693385A1 (en) 2020-08-12
NZ715896A (en) 2022-02-25
MX373245B (en) 2020-05-11
IL311371B1 (en) 2024-05-01
JP2020005635A (en) 2020-01-16
US11613575B2 (en) 2023-03-28
AU2022203851B2 (en) 2025-07-24
LT3016681T (en) 2020-03-25
IL276530A (en) 2020-09-30
JP7208129B2 (en) 2023-01-18
WO2015104346A1 (en) 2015-07-16
JP7757247B2 (en) 2025-10-21
LTPA2025538I1 (en) 2025-12-29
EP3091998A1 (en) 2016-11-16
EP4249515A2 (en) 2023-09-27
EP3016681A1 (en) 2016-05-11
KR102813816B1 (en) 2025-05-29
HUE048722T2 (en) 2020-08-28
SG11201510739TA (en) 2016-01-28
KR102363220B1 (en) 2022-02-15
SMT202500322T1 (en) 2025-11-10
IL276530B (en) 2022-03-01
DK3016681T5 (en) 2020-05-04
CA2915575A1 (en) 2015-01-08
KR20160027177A (en) 2016-03-09
US20230374131A1 (en) 2023-11-23
CN105722529A (en) 2016-06-29
EP3016681B1 (en) 2019-12-18
FR25C1054I1 (en) 2026-01-16
MX2015017487A (en) 2016-03-21
LT4249515T (en) 2025-08-25
AU2014286116A1 (en) 2016-02-04
JP7389833B2 (en) 2023-11-30
RS60131B1 (en) 2020-05-29
ES2776706T3 (en) 2020-07-31
IL290613A (en) 2022-04-01
CN106255507A (en) 2016-12-21
EP3091998B1 (en) 2025-08-20
JP7104000B2 (en) 2022-07-20
HUS2500051I1 (en) 2025-12-28
IL290613B2 (en) 2024-11-01
PL3016681T3 (en) 2020-06-15
ES3038421T3 (en) 2025-10-13
KR20250078622A (en) 2025-06-02
ME03675B (en) 2020-10-20
KR20230073341A (en) 2023-05-25
CN118063621A (en) 2024-05-24
CN106255507B (en) 2025-05-02
AU2022203851A1 (en) 2022-06-23
HK1231369A1 (en) 2017-12-22
AU2020202792A1 (en) 2020-05-21
JP6546162B2 (en) 2019-07-17
US10407501B2 (en) 2019-09-10
AU2020202792B2 (en) 2022-06-23
UA119646C2 (en) 2019-07-25
CN113248615A (en) 2021-08-13
BR112015032986A2 (en) 2017-08-22
HUE072527T2 (en) 2025-11-28
IL311371B2 (en) 2024-09-01
JP2016529882A (en) 2016-09-29
JP2022163009A (en) 2022-10-25
DK4249515T3 (en) 2025-09-15
JP7851903B2 (en) 2026-04-27
KR20220025210A (en) 2022-03-03
FIC20250036I1 (en) 2025-12-09
HRP20251127T1 (en) 2025-11-21
JP2022101539A (en) 2022-07-06
IL290613B1 (en) 2024-07-01
HRP20200382T1 (en) 2020-06-12
EA201690167A1 (en) 2016-06-30
EP4249515A3 (en) 2023-11-15
RS67220B1 (en) 2025-10-31
KR102531517B1 (en) 2023-05-12
JP2017505121A (en) 2017-02-16
US10465006B2 (en) 2019-11-05
JP2020048564A (en) 2020-04-02
JP6619342B2 (en) 2019-12-11
WO2015001085A1 (en) 2015-01-08
SI4249515T1 (en) 2025-11-28
US20160333095A1 (en) 2016-11-17
CY1122840T1 (en) 2021-05-05
CN120365424A (en) 2025-07-25
US20200199229A1 (en) 2020-06-25
ZA201800385B (en) 2019-09-25
CN113248615B (en) 2025-07-04
ES3052034T3 (en) 2025-12-30
IL243127B (en) 2020-08-31
EP4631978A2 (en) 2025-10-15
US20200123255A1 (en) 2020-04-23
PT4249515T (en) 2025-09-08
JP2024026114A (en) 2024-02-28
PL4249515T3 (en) 2025-12-22
NL301352I2 (en) 2025-12-16
SI3016681T1 (en) 2020-04-30
SMT202000287T1 (en) 2020-07-08
BR122023002590B1 (en) 2023-12-05
AU2020202792B9 (en) 2022-07-07
EP4631978A3 (en) 2025-12-24
EP4249515B1 (en) 2025-06-18
PT3016681T (en) 2020-03-26
DK3016681T3 (en) 2020-03-09
NO2025057I1 (en) 2025-12-11
IL311371A (en) 2024-04-01
CN105722529B (en) 2021-06-08
AU2025256200A1 (en) 2025-11-13
MX2020004503A (en) 2020-08-13
US20160168247A1 (en) 2016-06-16
FI4249515T3 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
IL311371A (en) Humanized or chimeric cd3 antibodies
ES3063317T3 (en) Humanized or chimeric cd3 antibodies
SG11201509609SA (en) Chimeric antigen receptor-targeting monoclonal antibodies
ZA201504697B (en) Antibodies comprising chimeric constant domains
EP2931314A4 (en) Chimeric and humanized anti-histone antibodies
IL244784A0 (en) Chimeric antigen receptor
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
HUE064437T2 (en) Antibodies against csf-1r
EP2970445A4 (en) Humanized anti-n2 antibodies
HK40081214B (en) Humanized or chimeric cd3 antibodies
HK1255635A1 (en) Humanized or chimeric cd3 antibodies